Revvity Omics' new laboratory in Finland strengthens the company's presence in Europe and expands its capacity to support clinical research and precision medicine initiatives across the region. Strategically located to serve the European Union, the facility will provide high-quality genomic, transcriptomic, and other advanced multi-omics services for pharmaceutical, biotechnology, clinical and academic customers.
In addition to providing comprehensive laboratory testing services that help clinicians meet their patient testing needs, the Finland site will serve as a key hub for scientific collaboration and technical expertise, enabling closer engagement with customers throughout Europe. The facility reflects Revvity Omics' commitment to advancing translational research, supporting clinical decision-making, and improving the efficiency of clinical development programs through innovative omics technologies. With its expanded European footprint, Revvity Omics is well positioned to help clinicians, researchers, and clinical study sponsors generate actionable insights that support more personalized patient care and the development of more effective therapies.
